Wednesday, November 19, 2014 3:21:31 PM
Interesting that many of the things you listed probably apply to most OTC stocks, but many don't apply for CTIX. If someone were new, they may believe it, but anyone who has been here a while knows some of your points are patently false. I think you demonstrated the boilerplate approach that shorts are taking very succinctly. That since CTIX is on the OTC, it has to be like most of the companies on it.
How many OTC companies have an individual who has past major success with large firms, put their own skin in the game, and have their product/service being tested by some of the most prestigious names in the game? Can't imagine many.
Dr. Frei's involvement alone lends much credibility.
Emil Frei III, MD - (In Memoriam)
Dr. Frei was known as one of the world’s leading oncologists, a pioneer of chemotherapy and a leader in medical research, clinical practice and education. His distinguished career included 40 years in top leadership positions such as Chief of Medicine at National Cancer Institute, Associate Scientific Director at M. D. Anderson, and Director and Physician-in-Chief at the Dana-Farber Cancer Institute.
Dr. Frei had unparalleled experience in the development of new cancer drugs. He is often referred to as the “Father of the Cure for Childhood Leukemia” because of his collaborative work with Dr. Emil J. Freireich.
- See more at: http://cellceutix.com/team/#sthash.mYRBd6Kp.dpuf
CTIX may fail to live up to being valued at the current market cap, or anything at all, but it's clear to me that CTIX is a very real and honest attempt at bringing something valuable to the market.
How many OTC companies have an individual who has past major success with large firms, put their own skin in the game, and have their product/service being tested by some of the most prestigious names in the game? Can't imagine many.
Dr. Frei's involvement alone lends much credibility.
Emil Frei III, MD - (In Memoriam)
Dr. Frei was known as one of the world’s leading oncologists, a pioneer of chemotherapy and a leader in medical research, clinical practice and education. His distinguished career included 40 years in top leadership positions such as Chief of Medicine at National Cancer Institute, Associate Scientific Director at M. D. Anderson, and Director and Physician-in-Chief at the Dana-Farber Cancer Institute.
Dr. Frei had unparalleled experience in the development of new cancer drugs. He is often referred to as the “Father of the Cure for Childhood Leukemia” because of his collaborative work with Dr. Emil J. Freireich.
- See more at: http://cellceutix.com/team/#sthash.mYRBd6Kp.dpuf
CTIX may fail to live up to being valued at the current market cap, or anything at all, but it's clear to me that CTIX is a very real and honest attempt at bringing something valuable to the market.

